Achao­gen earns $12M award for next-gen an­tibi­otics; En­do ac­quires Som­er­set for $190M

→ An­tibac­te­r­i­al R&D ac­cel­er­a­tor CARB-X has grant­ed Achao­gen $AKAO an award worth up to $12 mil­lion to fu­el its ear­ly-stage pro­grams in for mul­ti-drug re­sis­tant gram-neg­a­tive in­fec­tions. With an ini­tial pay­ment of $2.4 mil­lion, the South San Fran­cis­co biotech will fo­cus on de­vel­op­ing next-gen ver­sions of a com­mon class of an­tibi­otics called amino­gly­co­side, aim­ing to over­come cur­rent re­sis­tance mech­a­nisms. The part­ners are par­tic­u­lar­ly keen on the prospect of treat­ing En­ter­obac­te­ri­aceae, P. aerug­i­nosa and A. bau­man­nii, all “pri­or­i­ty 1 crit­i­cal pathogens” as rec­og­nized by the WHO. “The projects in the Pow­ered by CARB-X port­fo­lio are in the ear­ly stages of re­search, but if suc­cess­ful, these in­no­v­a­tive projects hold great po­ten­tial to treat se­ri­ous in­fec­tions and fight against the rise of drug-re­sis­tant bac­te­ria,” said Kevin Out­ter­son, ex­ec­u­tive di­rec­tor of CARB-X (for­mer­ly known as the Com­bat­ing An­tibi­ot­ic Re­sis­tant Bac­te­ria Bio­phar­ma­ceu­ti­cal Ac­cel­er­a­tor).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.